HCPT-peptide prodrug with tumor microenvironment -responsive morphology transformable characteristic for boosted...

As a common method for postoperative adjuvant treatments of bladder tumor, chemotherapy encounters low tumor targeting, short tumor retention time and bad bioavailability in clinical applications, which result in unsatisfactory high chemotherapeutical doses, frequent administration and subsequent severe side effects. Herein, we innovatively introduced the enzyme-assisted assembly to construct a bladder tumor-specific transformable peptide prodrug (i.e. HCPT-FF-GFLG-EEYSA). The prodrug targeted bladder tumor through the specific binding capacity of YSA to EphA2 and underwent on-demand structural transformation intracellularly from micelles to fibrils catalyzed by cathepsin B (CtsB), of which EphA2 and CtsB are overexpressed on the outer membrane and in cytoplasm of bladder tumor cells, respectively. Comparing with hydroxycamptothecin (HCPT), the prodrug can prolong the drug retention time and release the active drug in a sustained manner, which in turn decrease the administration frequencies of chemotherapeutics and reduce the side toxicities, etc. This strategy provides an alternative for bladder tumor chemotherapeutics and shows great potential to inhibit the relapse of postoperative tumors.